Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by…
- Trial name
- JETALS (NCT03548311)
- Testing
- methylcobalamin, saline solution
- Where
- 16 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Eisai Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis
Genetics of Familial and Sporadic ALS
We are collecting blood samples, clinical and family information from ALS (amyotrophic lateral sclerosis) patients and their families to identify causes of ALS and ALS/dementia.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease
- Trial name
- ALS (NCT00821132)
- Testing
- Genetic study of ALS families
- Where
- United States
- Volunteers
- 13,521 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Amyotrophic Lateral Sclerosis (ALS)
"New Perspectives of Adaptation to NIV in ALS"
The purpose of this study is to demonstrate that the adaptation to the Non Invasive Ventilation (NIV) at home is not worse when compared with an adaptation performed in inpatient settings.
- Trial name
- NCT02537132
- Testing
- Adaptation and training to Non Invasive Ventilation (NIV)
- Where
- 2 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Spinal Muscular Atrophy, Duchenne Muscular Dystrophy
Public AttitudesTowards SMA and DMD Awareness, Newborn and Carrier Screening and Physiotherapy Practices
The addition of SMA and DMD muscle diseases to newborn screening and premarital carrier screening has been controversial. In this study, researchers aim to measure the awareness level of SMA and DMD muscle diseases of individuals…
- Conditions
- Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Healthy Individuals
- Trial name
- NCT05110885
- Testing
- Questionnaire
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Bahçeşehir University
ALS (Amyotrophic Lateral Sclerosis), ALS
Kamlanoflast In Amyotrophic Lateral Sclerosis
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases
- Trial name
- NCT07396818
- Testing
- Kamlanoflast
- Volunteers
- 40 people
- Sponsor
- Inflammasome Therapeutics
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Amyotrophic Lateral Sclerosis and the Innate Immune System
Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles.
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT02869048
- Where
- 8 sites in Denmark
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Spinal Muscular Atrophy
Neonatal Spinal Muscular Atrophy (SMA) Screening
Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA.
- Trial name
- SMA (NCT03217578)
- Testing
- SMA Newborn Screening
- Where
- Taiwan
- Volunteers
- 250,000 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Amyotrophic Lateral Sclerosis
ALS Phase II Study of NX210c
This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- SEALS (NCT06365216)
- Testing
- NX210c
- Where
- 16 sites in France
- Volunteers
- 80 people
- Sponsor
- Axoltis Pharma
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS.
- Trial name
- PRO-101 (NCT05279755)
- Testing
- prosetin
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- ProJenX
Amyotrophic Lateral Sclerosis
Multiple Doses of AT-1501-A201 in Adults With ALS
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L).
- Trial name
- NCT04322149
- Testing
- AT-1501
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Anelixis Therapeutics, LLC
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen G DNL343
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT05842941
- Testing
- DNL343
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis
Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
- Trial name
- NCT06977451
- Testing
- nL-CHCHD-001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Tetraplegia/Tetraparesis, Quadriplegia
UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- UAE-PRIME (NCT06992596)
- Testing
- N1 Implant, R1 Robot
- Where
- United Arab Emirates
- Volunteers
- 10 people
- Sponsor
- Neuralink Corp
ALS, Amyotrophic Lateral Sclerosis
A Trial of Tocilizumab in ALS Subjects
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
- Trial name
- TCZALS-001 (NCT02469896)
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Barrow Neurological Institute
Amyotrophic Lateral Sclerosis
A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis
The purpose of this study is to determine determine the safety of intraspinal delivery of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with Amyotrophic Lateral Sclerosis (ALS) using a dose-escalation…
- Trial name
- NCT01609283
- Testing
- autologous mesenchymal stem cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis (ALS)
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy of SNUG01 in in adult subjects with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT07169175
- Testing
- SNUG01
- Where
- 4 sites in United States, China
- Volunteers
- 21 people
- Sponsor
- SineuGene Therapeutics Co., Ltd.
Amyotrophic Lateral Sclerosis
Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis
The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.
- Trial name
- NCT02242071
- Testing
- Stem Cell
- Where
- India
- Sponsor
- Neurogen Brain and Spine Institute
Amyotrophic Lateral Sclerosis
Study in ALS With Abatacept & IL-2
In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T-lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression.
- Trial name
- NCT06307301
- Testing
- Abatacept Injection [Orencia] and Proleukin (aldesleukin)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Methodist Hospital Research Institute
IBM, Inclusion Body Myositis
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM).
- Conditions
- IBM, Inclusion Body Myositis, Myopathy, Myositis
- Trial name
- NCT07823101
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis
Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies
The diagnosis and the follow-up of the patients reached of SLA is centralized, since a few years, at the the Caribbean Reference center of the rare neurological diseases (CERCA labélisé in 2006) in Martinique and at the Unity of…
- Trial name
- SLA-DOM (NCT03367650)
- Testing
- Blood sample and environmental survey
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.